1-14 of 14
Toshihiko Doi
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Correction: Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors

Giuseppe Curigliano, Hans Curigliano, Nicolas Mach, Toshihiko Doi, David Tai, Patrick M. Forde, John Sarantopoulos, Philippe L. Bedard, Chia-Chi Lin, F. Stephen Hodi, Sofie Wilgenhof, Armando Santoro, Catherine A. Sabatos-Peyton, Tyler A. Longmire, Alexandros Xyrafas, Haiying Sun, Sabine Gutzwiller, Luigi Manenti, Aung Naing
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (17): 3957.
https://doi.org/10.1158/1078-0432.CCR-24-2131
Published: 03 September 2024
View articletitled, Correction: Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors
Open the PDF for Correction: Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors in another window
Journal Articles

Updated Efficacy Outcomes of Anti-PD-1 Antibodies plus Multikinase Inhibitors for Patients with Advanced Gastric Cancer with or without Liver Metastases in Clinical Trials

Hiroki Yukami, Akihito Kawazoe, Yi-Tzu Lin, Shohei Koyama, Shota Fukuoka, Hiroki Hara, Naoki Takahashi, Takashi Kojima, Masako Asayama, Takako Yoshii, Hideaki Bando, Daisuke Kotani, Yoshiaki Nakamura, Yasutoshi Kuboki, Saori Mishima, Masashi Wakabayashi, Takeshi Kuwata, Masahiro Goto, Kazuhide Higuchi, Takayuki Yoshino, Toshihiko Doi, Hiroyoshi Nishikawa, Kohei Shitara
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (16): 3480–3488.
https://doi.org/10.1158/1078-0432.CCR-22-0630
Published: 15 August 2022
View articletitled, Updated Efficacy Outcomes of Anti-PD-1 Antibodies plus Multikinase Inhibitors for Patients with Advanced Gastric Cancer with or without Liver Metastases in Clinical Trials
Open the PDF for Updated Efficacy Outcomes of Anti-PD-1 Antibodies plus Multikinase Inhibitors for Patients with Advanced Gastric Cancer with or without Liver Metastases in Clinical Trials in another window
Includes: Supplementary data
Journal Articles

A Phase I, Open-Label, Dose-Escalation Study of the OX40 Agonist Ivuxolimab in Patients with Locally Advanced or Metastatic Cancers

Adi Diab, Omid Hamid, John A. Thompson, Willeke Ros, Ferry A.L.M. Eskens, Toshihiko Doi, Siwen Hu-Lieskovan, Samuel J. Klempner, Bishu Ganguly, Catherine Fleener, Xiao Wang, Tenshang Joh, Ken Liao, Shahram Salek-Ardakani, Carrie Turich Taylor, Jeffrey Chou, Anthony B. El-Khoueiry
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (1): 71–83.
https://doi.org/10.1158/1078-0432.CCR-21-0845
Published: 01 January 2022
View articletitled, A Phase I, Open-Label, Dose-Escalation Study of the OX40 Agonist Ivuxolimab in Patients with Locally Advanced or Metastatic Cancers
Open the PDF for A Phase I, Open-Label, Dose-Escalation Study of the OX40 Agonist Ivuxolimab in Patients with Locally Advanced or Metastatic Cancers in another window
Includes: Supplementary data
Journal Articles

Circulating Tumor DNA Analysis Detects FGFR2 Amplification and Concurrent Genomic Alterations Associated with FGFR Inhibitor Efficacy in Advanced Gastric Cancer

Tomoko Jogo, Yoshiaki Nakamura, Kohei Shitara, Hideaki Bando, Hisateru Yasui, Taito Esaki, Tetsuji Terazawa, Taroh Satoh, Eiji Shinozaki, Tomohiro Nishina, Yu Sunakawa, Yoshito Komatsu, Hiroki Hara, Eiji Oki, Nobuhisa Matsuhashi, Takashi Ohta, Takeshi Kato, Koushiro Ohtsubo, Takeshi Kawakami, Naohiro Okano, Yoshiyuki Yamamoto, Takanobu Yamada, Akihito Tsuji, Justin I. Odegaard, Hiroya Taniguchi, Toshihiko Doi, Satoshi Fujii, Takayuki Yoshino
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (20): 5619–5627.
https://doi.org/10.1158/1078-0432.CCR-21-1414
Published: 15 October 2021
View articletitled, Circulating Tumor DNA Analysis Detects FGFR2 Amplification and Concurrent Genomic Alterations Associated with FGFR Inhibitor Efficacy in Advanced Gastric Cancer
Open the PDF for Circulating Tumor DNA Analysis Detects FGFR2 Amplification and Concurrent Genomic Alterations Associated with FGFR Inhibitor Efficacy in Advanced Gastric Cancer in another window
Includes: Supplementary data
Journal Articles

Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors

Giuseppe Curigliano, Hans Gelderblom, Nicolas Mach, Toshihiko Doi, David Tai, Patrick M. Forde, John Sarantopoulos, Philippe L. Bedard, Chia-Chi Lin, F. Stephen Hodi, Sofie Wilgenhof, Armando Santoro, Catherine A. Sabatos-Peyton, Tyler A. Longmire, Alexandros Xyrafas, Haiying Sun, Sabine Gutzwiller, Luigi Manenti, Aung Naing
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (13): 3620–3629.
https://doi.org/10.1158/1078-0432.CCR-20-4746
Published: 01 July 2021
View articletitled, Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors
Open the PDF for Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors

Matthew D. Hellmann, Nicoletta Bivi, Boris Calderon, Toshio Shimizu, Brant Delafontaine, Zhuqing Tina Liu, Anna M. Szpurka, Victoria Copeland, F. Stephen Hodi, Sylvie Rottey, Philippe Aftimos, Yongzhe Piao, Leena Gandhi, Violeta Regnier Galvao, Ching Ching Leow, Toshihiko Doi
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (10): 2773–2781.
https://doi.org/10.1158/1078-0432.CCR-20-3716
Published: 15 May 2021
View articletitled, Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors
Open the PDF for Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Blocking TIM-3 in Treatment-refractory Advanced Solid Tumors: A Phase Ia/b Study of LY3321367 with or without an Anti-PD-L1 Antibody

James J. Harding, Victor Moreno, Yung-Jue Bang, Min Hee Hong, Amita Patnaik, José Trigo, Anna M. Szpurka, Noboru Yamamoto, Toshihiko Doi, Siqing Fu, Boris Calderon, Nieves Velez de Mendizabal, Emiliano Calvo, Danni Yu, Leena Gandhi, Zhuqing Tina Liu, Violeta Regnier Galvao, Ching Ching Leow, Maria J. de Miguel
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (8): 2168–2178.
https://doi.org/10.1158/1078-0432.CCR-20-4405
Published: 15 April 2021
View articletitled, Blocking TIM-3 in Treatment-refractory Advanced Solid Tumors: A Phase Ia/b Study of LY3321367 with or without an Anti-PD-L1 Antibody
Open the PDF for Blocking TIM-3 in Treatment-refractory Advanced Solid Tumors: A Phase Ia/b Study of LY3321367 with or without an Anti-PD-L1 Antibody in another window
Includes: Supplementary data
Journal Articles

The Impact of Molecular Subtype on Efficacy of Chemotherapy and Checkpoint Inhibition in Advanced Gastric Cancer

Yohei Kubota, Akihito Kawazoe, Akinori Sasaki, Saori Mishima, Kentaro Sawada, Yoshiaki Nakamura, Daisuke Kotani, Yasutoshi Kuboki, Hiroya Taniguchi, Takashi Kojima, Toshihiko Doi, Takayuki Yoshino, Genichiro Ishii, Takeshi Kuwata, Kohei Shitara
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (14): 3784–3790.
https://doi.org/10.1158/1078-0432.CCR-20-0075
Published: 15 July 2020
View articletitled, The Impact of Molecular Subtype on Efficacy of Chemotherapy and Checkpoint Inhibition in Advanced Gastric Cancer
Open the PDF for The Impact of Molecular Subtype on Efficacy of Chemotherapy and Checkpoint Inhibition in Advanced Gastric Cancer in another window
Includes: Supplementary data
Journal Articles

Safety and Tolerability of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Asian Patients with Pretreated Recurrent or Refractory Gastric Cancer

Yoon-Koo Kang, Yung-Jue Bang, Shunsuke Kondo, Hyun Cheol Chung, Kei Muro, Isabelle Dussault, Christoph Helwig, Motonobu Osada, Toshihiko Doi
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (13): 3202–3210.
https://doi.org/10.1158/1078-0432.CCR-19-3806
Published: 01 July 2020
View articletitled, Safety and Tolerability of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Asian Patients with Pretreated Recurrent or Refractory Gastric Cancer
Open the PDF for Safety and Tolerability of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Asian Patients with Pretreated Recurrent or Refractory Gastric Cancer in another window
Includes: Supplementary data
Journal Articles

Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study

Jonathan Strosberg, Nobumasa Mizuno, Toshihiko Doi, Enrique Grande, Jean-Pierre Delord, Ronnie Shapira-Frommer, Emily Bergsland, Manisha Shah, Marwan Fakih, Shunji Takahashi, Sarina A. Piha-Paul, Bert O'Neil, Sajeve Thomas, Martijn P. Lolkema, Menghui Chen, Nageatte Ibrahim, Kevin Norwood, Julien Hadoux
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (9): 2124–2130.
https://doi.org/10.1158/1078-0432.CCR-19-3014
Published: 01 May 2020
View articletitled, Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study
Open the PDF for Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study in another window
Includes: Supplementary data
Journal Articles

A Phase I Study of the Anti-CC Chemokine Receptor 4 Antibody, Mogamulizumab, in Combination with Nivolumab in Patients with Advanced or Metastatic Solid Tumors

Toshihiko Doi, Kei Muro, Hiroshi Ishii, Terufumi Kato, Takahiro Tsushima, Mitsuhiro Takenoyama, Satoshi Oizumi, Kazuto Gemmoto, Hideaki Suna, Kouki Enokitani, Tetsuyoshi Kawakami, Hiroyoshi Nishikawa, Noboru Yamamoto
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (22): 6614–6622.
https://doi.org/10.1158/1078-0432.CCR-19-1090
Published: 15 November 2019
View articletitled, A Phase I Study of the Anti-CC Chemokine Receptor 4 Antibody, Mogamulizumab, in Combination with Nivolumab in Patients with Advanced or Metastatic Solid Tumors
Open the PDF for A Phase I Study of the Anti-CC Chemokine Receptor 4 Antibody, Mogamulizumab, in Combination with Nivolumab in Patients with Advanced or Metastatic Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer

Neil H. Segal, Aiwu R. He, Toshihiko Doi, Ronald Levy, Shailender Bhatia, Michael J. Pishvaian, Rossano Cesari, Ying Chen, Craig B. Davis, Bo Huang, Aron D. Thall, Ajay K. Gopal
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (8): 1816–1823.
https://doi.org/10.1158/1078-0432.CCR-17-1922
Published: 12 April 2018
View articletitled, Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer
Open the PDF for Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer in another window
Includes: Supplementary data
Journal Articles

Phase Ia Study of FoxP3+ CD4 Treg Depletion by Infusion of a Humanized Anti-CCR4 Antibody, KW-0761, in Cancer Patients

Koji Kurose, Yoshihiro Ohue, Hisashi Wada, Shinsuke Iida, Takashi Ishida, Takashi Kojima, Toshihiko Doi, Susumu Suzuki, Midori Isobe, Takeru Funakoshi, Kazuhiro Kakimi, Hiroyoshi Nishikawa, Heiichiro Udono, Mikio Oka, Ryuzo Ueda, Eiichi Nakayama
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (19): 4327–4336.
https://doi.org/10.1158/1078-0432.CCR-15-0357
Published: 30 September 2015
View articletitled, Phase Ia Study of FoxP3+ CD4 Treg Depletion by Infusion of a Humanized Anti-CCR4 Antibody, KW-0761, in Cancer Patients
Open the PDF for Phase Ia Study of FoxP3+ CD4 Treg Depletion by Infusion of a Humanized Anti-CCR4 Antibody, KW-0761, in Cancer Patients in another window
Includes: Supplementary data
Journal Articles

Phase I Study of NK012, a Novel SN-38–Incorporating Micellar Nanoparticle, in Adult Patients with Solid Tumors

Tetsuya Hamaguchi, Toshihiko Doi, Takako Eguchi-Nakajima, Ken Kato, Yasuhide Yamada, Yasuhiro Shimada, Nozomu Fuse, Atsushi Ohtsu, Shin-ichi Matsumoto, Masaya Takanashi, Yasuhiro Matsumura
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (20): 5058–5066.
https://doi.org/10.1158/1078-0432.CCR-10-0387
Published: 15 October 2010
View articletitled, Phase I Study of NK012, a Novel SN-38–Incorporating Micellar Nanoparticle, in Adult Patients with Solid Tumors
Open the PDF for Phase I Study of NK012, a Novel SN-38–Incorporating Micellar Nanoparticle, in Adult Patients with Solid Tumors in another window